Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
71 results about "Granzyme" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Granzymes are serine proteases released by cytoplasmic granules within cytotoxic T cells and natural killer (NK) cells. They induce programmed cell death (apoptosis) in the target cell, thus eliminating cells that have become cancerous or are infected with viruses or bacteria. Granzymes also kill bacteria and inhibit viral replication. In NK cells and T cells, granzymes are packaged in cytotoxic granules with perforin. Granzymes can also be detected in the rough endoplasmic reticulum, golgi complex, and the trans-golgi reticulum. The contents of the cytotoxic granules function to permit entry of the granzymes into the target cell cytosol. The granules are released into an immune synapse formed with a target cell, where perforin mediates the delivery of the granzymes into endosomes in the target cell, and finally into the target cell cytosol. Granzymes are part of the serine esterase family. They are closely related to other immune serine proteases expressed by innate immune cells, such as neutrophil elastase and cathepsin G.
T-cell epitope identification
ActiveUS20180052176A1Efficient removalMicrobiological testing/measurementBiological testingNucleotideMembrane bound
The present invention is a method for determining the identity of the epitopes recognized by T-cells. The method consists of expressing an encoded library of candidate epitope sequences in a recipient reporter cell capable of providing a detectable signal upon cytotoxic attack from a single cognate T-cell followed by contacting the reporter cells with T-cells of interest. The reporter cells with a single indicating cytotoxic attack from a T-cell are isolated and then analyzed by next-generation sequencing in order to identify the epitope sequences. Specifically disclosed is a method in which a library of candidate epitope-encoding nucleic acids are expressed in cells which feature a membrane-bound major histocompatibility complex (MHC) protein, said library produced by transfection of plasmids featuring both a nucleotide encoding the candidate epitope and a nucleotide encoding a FRET-based fluorescent protein cleaved by granzyme.
Owner:PROVINCIAL HEALTH SERVICES AUTHORITY
Magnetic granule competing method chemiluminescence immune analysis determination reagent kit for detecting hormone and preparing method thereof
InactiveCN101377491AGuaranteed SensitivityEasy to operateChemiluminescene/bioluminescenceBiological testingAntigenBiotin-streptavidin complex
The invention relates to the immunoassay medical field, particularly provides a magnetic particle competition method chemiluminescence immunoassay assay kit and a preparation method thereof used for detecting hormones. The kit according to the invention comprises: 1) a calibrator; 2) magnetic particles which are coated with streptavidin; 3) hormone antigens of enzyme markers; and 4) a chemiluminescence substrate. Further, the method for preparing the kit according to the invention has the following steps: 1) pure raw materials are used to prepare the calibrator; 2) the antigens are used to coat the magnetic particles; 3) the antigens of the enzyme markers are prepared; 4) the calibrator, the chemiluminescence substrate and the antigens of the enzyme markers are packaged in a separated way; and 5) a finished product is packaged. The kit has the advantages of convenience, rapidness, sensitivity, stability, and the like.
Owner:CHEMCLIN DIAGNOSTICS CO LTD
Visualization and quantitation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
ActiveUS20070184493A1Microbiological testing/measurementTetrapeptide ingredientsFluorescenceApoptosis pathways
This invention provides a non-radioactive assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This assay is predicated on the discovery that apoptosis pathway activation and, in particular, granzyme B activity, provides a measure of cytotoxic effector cell activity. In one embodiment, measurement of CTL-induced granzyme B activation in target cells is achieved through detection of the specific cleavage of fluorogenic granzyme B substrates. This assay reliably detects antigen-specific CTL killing of target cells, and provides a more sensitive, more informative and safer alternative to the standard 51Cr-release assay most often used to quantify CTL responses. The assay can be used to study CTL-mediated killing of primary host target cells of different cell lineages, and enables the study of antigen-specific cellular immune responses in real time at the single-cell level. As such, the assay can provide a valuable tool for studies of infectious disease pathogenesis and development of new vaccines and immunotherapies.
Owner:ONCOIMMUNIN
Visualization and quantitation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
ActiveUS7927871B2Microbiological testing/measurementTetrapeptide ingredientsFluorescenceCytotoxicity
Owner:ONCOIMMUNIN
Granzyme b inhibitors
The present invention encompasses compounds of Formula (I) and pharmaceutically acceptable salts or hydrates thereof. The compounds are inhibitors of granzyme B and are useful for treating autoimmune and chronic inflammatory diseases. Pharmaceutical compositions and methods of use are also included.
Owner:CHAPMAN KEVIN T +2
Efficient amplification method of TILs serving as sources of cancerous pleural effusion
The invention aims to provide an efficient amplification method of TILs serving as sources of cancerous pleural effusion. The TILs prepared with the method have the advantages of being high in multiplication speed, large in number, high in cell activity and the like. The method is mainly characterized in that by utilizing a cultivation bottle coated by laminin protein and fibronectin, the TILs are cultivated. The adsorption effect of the two kinds of protein can make cells in half-adherence state, therefore, the cells are favorable for being stimulated by various factors, and the two kinds of protein has the multiplication promoting effect on the TILs; by using a resistant OX-40 monoclone antibody, co-stimulatory signals of CD3+CD8+T cell subgroups in the TILs can be stimulated, cell activation is promoted, the expression of cell perforin and granular enzyme is improved, and the killing capacity of the TILs is enhanced. So far, the study report that the laminin protein, the fibronectin and the resistant OX-40 monoclone antibody are combined and used for preparing the TILs has not been given, and the method for increasing the cell number and improving the killing activity by adding the three factors in preparation of the TILs is put forward for the first time.
Owner:青岛麦迪赛斯医疗技术有限公司
Cell line of lymphocytes comprising gamma-delta T cells, composition and production method thereof
The present invention relates to a cell line of lymphocytes comprising γδ T cells, composition and production method thereof, and medical use namely for the use in medicine, namely in cancer immunotherapy.The cell line comprise a sample of human peripheral blood Vδ1+γδ T cells expressing functional natural cytotoxicity receptors (NCRs). These Vδ1+ NCR+ T lymphocytes can directly mediate killing of leukemia cell lines and chronic lymphocytic leukemia patient neoplastic cells.The present invention shows that human Vδ1+ NCR+ T cells can be differentiated and expanded from total γδ peripheral blood lymphocytes (PBLs), upon regular in vitro or ex vivo stimulation with γδTCR agonists and γc-family cytokines. This subset surprisingly expresses NKp30, NKp44 and NKp46, and high levels of Granzyme B that associate with highly enhanced cytotoxicity against lymphoid leukemias.
Owner:INST DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Indoline compounds as granzyme b inhibitors
ActiveUS20160083422A1Treat, reduce, and/or inhibit the appearance of ageing in the skinTetrapeptide ingredientsTripeptide ingredientsSolubilityWater soluble
Granzyme B inhibitor compounds, compositions that include the compounds, and methods for using the compounds. The compounds of the invention have advantageous water solubility and effectively inhibit Granzyme B.
Owner:VIDA THERAPEUTICS
Cyclic urea compounds as granzyme b inhibitors
An ultraviolet (UV) disinfection unit for disinfecting catheter line connections is provided. The unit can be used to disinfect solution set and transfer set catheters used for peritoneal dialysis. The unit can comprise a concavely curved bottom surface. A tubing trough of the unit can allow for ambidextrous positioning.
Owner:VIDA THERAPEUTICS
Fusion protein comprising granzyme b and use thereof
ActiveUS20150329847A1Polypeptide with localisation/targeting motifSugar derivativesCell membraneGranzyme B
A fusion protein including granzyme B, a cell penetrating peptide, a cleavage site, and a targeting moiety, a composition for cell membrane penetration comprising the fusion protein, and an anticancer composition comprising the fusion protein.
Owner:SAMSUNG ELECTRONICS CO LTD
Purifying and use for human vascular endothelial growth factor and granzyme B fusion protein
InactiveCN1465702APeptide/protein ingredientsGenetic material ingredientsSerine proteinasesFiltration
By adopting gene recombination technology to implement recombination of vascular endothelial growth factor (VEGF)2-5 exon and gran zyme B (GraB) gene and make VEGF2-5 and GraB be connected and formedinto fusion gene by means of a part of elastic connecon, and utilizing the specific combination of VEGF2-5 and VEGFR to guide GraB and make it target-act on the nescent vascular endothelial cell so as to attain the goal of target-resisting angiogenesis. Said invention uses prokaryocyte secretion type expression system to express recombinant VEGF-Gra fusion protein, and uses immobilized metal ion affinity chromatography and gel filtration method to purity the fusion protein, and uses GraB serine proteinase activity test experiment and chick embryo allantoic membrane angiogenesis anther membrane inhibition experiment to determine the bio-activity of recombinant VEGF-GraB fusion protein.
Owner:曾位森
Functionalized Enzyme-Powered Nanomotors
PendingUS20220016223A1Strong specificityEliminate side effectsPowder deliveryMaterial nanotechnologyHeterologousNanomotor
The present invention provides an enzyme-powered nanomotor, comprising a particle with a surface, an enzyme, and a heterologous molecule; characterized in that the enzyme and the heterologous molecule are discontinuously attached over the whole surface of the particle. The invention also provides the nanomotor for use in therapy, diagnosis and prognosis, in particular, for the treatment of cancer. Additionally, the invention provides the use of the nanomotor for detecting an analyte in an isolated sample.
Owner:FUNDACIO INST DE BIOENGINYERIA DE CATALUNYA IBEC +1
Immune cell capable of simultaneously expressing fusion protein and chimeric antigen receptor and application of immune cell
PendingCN114525260ASpecific recognitionEnhance tumor killing activityVirusesAntibody mimetics/scaffoldsReceptorAntigen receptors
The invention discloses an immune cell capable of simultaneously expressing a fusion protein of an intracellular truncated TGF-beta receptor and a cytokine intracellular stimulation domain and a chimeric antigen receptor on a cell membrane. The immune cell can enhance the proliferation capacity of the cell, reduce the influence of a tumor microenvironment, enhance the tumor killing activity of the CAR-T cell and reduce the depletion under the condition of receiving antigen stimulation, so that the negative regulation of the tumor microenvironment on the immune cell is weakened, the depletion of the immune cell is reduced, the tumor killing function of the immune cell is enhanced, and the inhibition of the tumor microenvironment on the immune cell is reduced; by combining with cell factor receptors, corresponding JAK and STAT signal channels are activated, the cells are induced to secrete various active substances such as IFN-gamma, perforin and granzyme, the growth of tumor cells is inhibited, the anti-tumor capability is enhanced, the killing function of immune cells is optimized, and the inhibition of a tumor microenvironment on the immune cells is reduced.
Owner:SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD
Pyrrole compounds as granzyme b inhibitors
ActiveUS20170015705A1Reduce, and/or inhibit the appearance of ageing in the skinDipeptide ingredientsPharmaceutical delivery mechanismDISCOID LUPUS ERYTHEMATOSISPyrrole
Owner:VIDA THERAPEUTICS
Natural killer cell line modified by human interferon-alpha gene and establishing method thereof
InactiveCN101948806ASolving Difficult-to-Transfect ProblemsLow costMicroorganism based processesFermentationInterferon alphaCancer research
The invention discloses a natural killer cell line (NKL) modified by a human interferon (IFN)-alpha gene, which can stably excrete and express the human IFN-alpha and is established by transfecting the human IFN-alpha gene into an NKL cell. The cell line can be expressed in cells according to the RT-PCR and ELISA detection and identification, and the synthesized IFN-alpha is excreted in extracellular culture supernate. Further research indicates that the NKL cell line modified by the human IFN-alpha gene can effectively kill liver cancer cells, and such anti-tumor effect is related to the expression level improvement of the NKL-IFN-alpha cell, IFN-gamma, Granzyme, TNF-alpha and Perforin genes and proteins. Moreover, the modified NKL cell line is more sensitive to external stimulus. Therefore, the biological characteristics of the cell line are more favorable for the application of clinical adoptive immunotherapy.
Owner:SHANDONG UNIV
Cancer targeting enhanced anti-tumor fusion protein, preparation method and use thereof
ActiveCN110305220AEnhance the amount of secretionPromote apoptosisAntibody ingredientsImmunoglobulinsCancer targetingAntiendomysial antibodies
The invention discloses a cancer targeting enhanced anti-tumor fusion protein, a preparation method and use thereof. The cancer targeting enhanced anti-tumor fusion protein comprises: a) an antibody and b) the fusion protein that induces and activates T cells. The components of the cancer targeting enhanced anti-tumor fusion protein of the invention have the synergistic effect, and produces a superimposed amplification effect, which shows that the biological activity far exceeds a single molecule; the fusion protein is capable of inducing and activating T cells to kill tumors and enhancing therole of cytokines secreted by T cells, the experiments show that the cancer targeting enhanced anti-tumor fusion protein of the present invention enhances the secretion amount of interferon-gamma(IFN-gamma) and granzyme,the apoptosis of cancer cells can be accelerated, and the fusion protein has obvious killing effect on various cancers and solid tumors.
Owner:孙嘉琳 +1
Functionalized enzyme-powered nanomotors
PendingCN113840798AStrong specificityReduce secondary effectsPowder deliveryMaterial nanotechnologyHeterologousNanomotor
Owner:ФУНДАЦИО ИНСТИТУТ ДЕ БИОЕНДЖИНИЕРИА ДЕ КАТАЛУНИА +1
Proline compounds as granzyme b inhibitors
ActiveUS20170015706A1Reduce, and/or inhibit the appearance of ageing in the skinPharmaceutical delivery mechanismTripeptide ingredientsMedicineDepressant
Owner:VIDA THERAPEUTICS
Granzyme B targeting complex, radiopharmaceutical and preparation method and application of granzyme B targeting complex and radiopharmaceutical
ActiveCN114028590AEasy to makeImprove overall performancePeptide/protein ingredientsRadioactive preparation carriersRadioactive drugPharmaceutical drug
The invention belongs to the field of nuclear medicine, and relates to a granzyme B targeting complex, a radiopharmaceutical and a preparation method and application of the granzyme B targeting complex and the radiopharmaceutical. The structure of the granzyme B targeting complex is shown as a formula (I), wherein R is any one of a difunctional chelating group for radionuclide labeling or a derivative thereof. The granzyme B targeting complex provided by the invention can be labeled by radionuclide to prepare a granzyme B targeting radiopharmaceutical; wherein the granzyme B targeting radiopharmaceutical provided by the invention is simple to prepare, and has better pharmacokinetic characteristics and in-vivo metabolism stability compared with other granzyme B targeting drugs; and therefore, the expression level of granzyme B in body can be noninvasively monitored through nuclear medicine imaging.
Owner:PEKING UNIV
Envelope production process for granzyme for temperature-resistant feed
ActiveCN102362696AStrong water absorptionChemically stableFeeding-stuffAnimal feeding stuffOrganic solventThermal stability
The invention discloses an envelope production process for granzyme for a temperature-resistant feed. The process comprises the following steps of: mixing raw enzyme and a carrier, namely mixing the raw enzyme and the carrier to obtain paste, wherein the carrier consists of calcium carbonate, ethyl cellulose, corn starch and water, and the granzyme is prepared from the following raw materials in percentage by weight: 20 percent of calcium carbonate, 10 to 20 percent of ethyl cellulose, 20 to 30 percent of corn starch, 20 to 40 percent of raw enzyme and the balance of water; granulating; performing shot blasting; coating; and drying. By the process, the thermal stability, particularly the humidity resistance of the enzyme can be improved. Enteric polyacrylic resin latex is used as a coating material, so the use of an organic solvent can be avoided in the coating process, the production is safe, and three wastes are not generated.
Owner:上海欧耐施生物技术有限公司
Application of quercitrin in preparation of human gamma delta T cell proliferator
InactiveCN103860574APromote proliferationHigh expressionOrganic active ingredientsImmunological disordersQuercitrinT cell
The invention discloses an application of quercitrin in preparation of a human gamma delta T cell proliferator, and relates to the technical field of medicines. Quercitrin can remarkably promote proliferation of human gamma delta T cells and promote expression of perforin and granzyme B, so that the quercitrin is of certain dose dependency. The gamma delta T cell treated by the quercitrin can promote expression of p-ERK (Extracellular signal-Regulated Kinase)1 / 2 and p-Akt in active form and promote expression of an anti-apoptoasis protein Bcl-2, so that the gamma delta T cell is of certain dose dependency. The invention discovers the novel medical use of quercitrin and provides experimental references to development of tumor immunotherapy medicines.
Owner:NO 97 HOSPITAL OF PLA
Heat shock protein 90 (HSP90) chemiluminescence detection kit
InactiveCN105403706AHigh sensitivityStrong specificityChemiluminescene/bioluminescenceBiological testingHsp90Monoclonal antibody
The present invention provides a heat shock protein 90 (HSP90) chemiluminescence detection kit, which comprises: 1) a heat shock protein 90 (HSP90)) standard substance, wherein the heat shock protein 90 is short for HSP90; 2) magnetic particles coated with a HSP90 monoclonal antibody; 3) an enzyme-labeled HSP90 monoclonal antibody; 4) chemiluminescent substrates A and B acted by the enzyme; 5) a washing solution; and 6) a white opaque micro-pore plate. According to the present invention, with the kit, the HSP90 content in patient serum can be detected, and the important guide significance is provided for detection of non-small cell lung cancers and other tumors; and the kit has characteristics of high sensitivity, strong specificity, safety, and reliability.
Owner:BEIJING DIAGREAT BIOTECH CO LTD
Compositions for and methods of granzyme B inhibition
The present invention is related to the discovery that serpina3n, a secreted protein, binds to and inhibits granzyme B activity. The invention thus provides cells that include a polynucleotide encoding a granzyme B inhibitory serpin, pharmaceutical compositions including a granzyme B inhibitory serpin or a polynucleotide encoding a granzyme B inhibitory serpin, methods for treating a patient in need of immunosuppression by administration of a granzyme B inhibitory serpin, and methods of transplanting cells (e.g., islet cells) expressing a granzyme B inhibitory serpin.
Owner:THE UNIV OF ALBERTA
In-vitro amplification method of iNKT cells
InactiveCN110872575AIncrease the amplification factorIncrease lethalityCulture processBlood/immune system cellsDendritic cellDendrite
Owner:中冠赛尔生物科技(北京)有限公司
Immune cell and application thereof
PendingCN113249330ASpecific recognitionEnhance tumor killing activityPolypeptide with localisation/targeting motifImmunoglobulin superfamilyTumor reductionCytokine Receptor Binding
The invention relates to the technical field of biological cells, in particular to an immune cell and application thereof. A chimeric antigen receptor is expressed on the cytomembrane of the immune cell, and in addition, an immune checkpoint antibody protein fused with a cytokine receptor is also expressed on the cytomembrane. The expression CAR cell of the immune checkpoint antibody protein fused with the cytokine receptor is also expressed on the cytomembrane; through the immune checkpoint antibody protein which is fused with the cytokine receptor and is expressed on the immune cytomembrane, two negative feedback approaches PD-1 and CTLA-4 are blocked so as to weaken negative regulation and control of a tumor microenvironment for the immune cell, reduce exhaustion of the immune cell, enhance the tumor killing function of the immune cell and reduce inhibition of the immune cell by the tumor microenvironment; and in addition, through binding with the cytokine receptor, corresponding JAK and STAT signal channels are activated, and the cells are induced to secrete various active substances, including IFN-[gamma], perforin, granzyme and the like so as to inhibit growth of tumor cells, enhance an anti-tumor capacity, reduce the exhaustion and reduce the inhibition of the immune cell by the tumor microenvironment.
Owner:SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD
Enhanced anti-tumor fusion protein, preparation method and use thereof
ActiveCN110305221AStrong killing effectGood killing effectPeptide/protein ingredientsAntibody mimetics/scaffoldsCancer cellTumor necrosis factor alpha
The invention discloses an enhanced anti-tumor fusion protein, a preparation method and use thereof. The fusion protein includes at least two of a costimulatory molecule B7.1 that induces and activates T cells, a costimulatory molecule B7.2 that induces and activates the T cells, and a superantigen Staphylococcus aureus enterotoxin A. The fusion protein of the present invention constructs at leasttwo of B7.1, B7.2 and SEA into the fusion protein, and exerts the superimposed amplification effect. The biological activity is far more than that of a single source protein, the T cells are inducedand activated to kill tumors, the T cells secrets cytokines such as tumor necrosis factor alpha (TNF-alpha) and granzymes and induces the cancer cells as target cells to produce Fas and the like to cause cancer cells to apoptosis, The experiments have shown that each of the fusion proteins of the present invention has the significant killing effect on various cancers and solid tumors.
Owner:孙嘉琳 +1
Immune cell for expressing cytokine receptor fusion type chimeric antigen receptor and application thereof
InactiveCN113416708AImprove proliferative abilityEnhance tumor killing activityPolypeptide with localisation/targeting motifImmunoglobulin superfamilyTumor reductionCytokine Receptor Binding
The invention discloses an immune cell for expressing a cytokine receptor fusion type chimeric antigen receptor and application of the immune cell. A cytokine receptor fusion type chimeric antigen receptor is expressed on a cell membrane of the immune cell, and a cytokine receptor intracellular domain is fused in an intracellular domain structure of the cytokine receptor fusion type chimeric antigen receptor. The immune cell can enhance the proliferation capacity of the cell, reduce the influence of a tumor microenvironment and enhance the tumor killing activity of the immune cell under the condition of receiving antigen stimulation, so that the negative regulation of the tumor microenvironment on the immune cell is weakened, the exhaustion of the immune cell is reduced, and corresponding JAK and STAT signal channels are activated by combining with a cytokine receptor, the cells are induced to secrete various active substances such as IFN-gamma, perforin and granzyme, so that the growth of tumor cells is inhibited, the anti-tumor capability is enhanced, and the inhibition of a tumor microenvironment on immune cells is reduced.
Owner:SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD
Methods of Determining Cell Mediated Response
InactiveUS20150329895A1SsRNA viruses negative-senseBiocideCell mediated immunityCell-mediated immune response
The invention relates to the use of one of more biomarkers, such as granzyme B, to determine an immune response, such as a cell-mediated immune response, of a subject to an immunostimulatory composition. The invention also relates to methods of treating a subject determined to develop a poor immune response to an immunostimulatory composition. Further, the invention relates to kits for use in practicing methods of the invention.
Owner:ADVANCED MEDICAL RES INST OF CANADA
COMPOSITION COMPRISING NK CELLS AND plant-derived EXOSOMES, USE THEREOF AND PRODUCTS COMPRISING SAME
PendingCN113462645AOvercoming the reduced ability to attack cancer cellsGood treatment effectCulture processMammal material medical ingredientsCancer cellNatural Killer Cell Inhibitory Receptors
The present application provides a composition comprising NK cells and plant-derived extracellular vesicles. The extracellular vesicles can act as NK cell activators to stimulate NK cells to release proteins, such as perforin and / or granzyme, thereby exerting cytotoxicity. The plant-derived extracellular vesicles overcome the problem that the ability of NK cells to attack cancer cells is reduced in the past, enhances the ability of the NK cells to attack the cancer cells, and improves the treatment effect of the NK cells on cancers.
Owner:上海瑞开投资管理有限公司 +1
Immune cell treated by magnetic field and application thereof
ActiveCN111733154APromote secretionBoost breathing levelsCulture processMammal material medical ingredientsReceptorT cell
The invention relates to an immune cell treated by a magnetic field and application thereof. According to the invention, a medium static magnetic field with the intensity of 0.3T can promote secretionof CD8<+> T cell granzyme and cell factors of a mouse, increase the level of ATP and mitochondrial respiration and up-regulate expression of related genes Uqcrb and / or Ndefs 6 of a mitochondrial respiratory chain. In addition, magnetic receptor candidate genes Isca1 and Cry1 / Cry2 participate in regulation and control of expression of Uqcrb and / or Ndefs 6. An in-vivo experiment shows that the static magnetic field can inhibit growth and development of tumors by promoting secretion of the CD8<+>T cell granzyme and the cell factors. A killing ability test shows that static magnetic field treatment can enhance the killing ability of CD8<+> T cells, and the CD8<+> T cells treated by the magnetic field have a remarkable anti-tumor effect when being transfused back into a tumor grafted mouse.The invention not only discloses that the medium-intensity static magnetic field can enhance the killing ability of the CD8<+> T cells by promoting mitochondrial respiration, but also provides a novel method for enhancing the anti-tumor function of the CD8<+> T cells by a physical method.
Owner:HEYE HEALTH TECH CO LTD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com